Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3275894 | Médecine des Maladies Métaboliques | 2010 | 10 Pages |
Abstract
In conclusion, the results of this study in real life condition showed a usage profile of insulin glargine in France conforms to joint HAS and AFSSAPS good use and recommendations for management of diabetic patient. Glycemic control improved initially following the introduction of insulin glargine and was maintained during the 12-month follow-up. An increasing number of patients reaching HbA1c (<7%) target was observed, with no increase in severe hypoglycemia, and a minor weight gain. These results, obtained with insulin glargine in real practice conditions, corroborate those found in clinical trials and provide a strong complement to studies evaluating the benefit/risk ratio.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
B. Charbonnel, E. Eschwège, G. Charpentier, B. Vialettes, G. Chabrier, D. Pouchain, S. Suissa, J. Massol, M. Lièvre,